MedTrace Logo

Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer

NCT07180082 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 186

Last updated 2025-11-18

No results posted yet for this study

Summary

This is a prospective, randomised, controlled, multicentre study to evaluate the efficacy and safety of continuous versus intermittent pyrotinib therapy in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer.

Conditions

Interventions

DRUG

Pyrotinib

anti-HER2 tyrosine kinase inhibitor

Sponsors & Collaborators

  • Wenjin Yin

    lead OTHER

Principal Investigators

  • Wenjin Yin, M.D. · Renji Hospital,School of Medicine, Shanghai Jiaotong University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-28
Primary Completion
2028-09-30
Completion
2029-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07180082 on ClinicalTrials.gov